The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study

Rhiem, Kerstin; Engel, Christoph; Graeser, Monika; Zachariae, Silke; Kast, Karin; Kiechle, Marion; Ditsch, Nina; Janni, Wolfgang; Mundhenke, Christoph; Golatta, Michael; Varga, Dominic; Preisler-Adams, Sabine; Heinrich, Tilman; Bick, Ulrich; Gadzicki, Dorothea; Briest, Susanne; Meindl, Alfons; Schmutzler, Rita K.
November 2012
Breast Cancer Research;2012, Vol. 14 Issue 6, p1
Academic Journal
Introduction: While it has been reported that the risk of contralateral breast cancer in patients from BRCA1 or BRCA2 positive families is elevated, little is known about contralateral breast cancer risk in patients from high risk families that tested negative for BRCA1/2 mutations. Methods: A retrospective, multicenter cohort study was performed from 1996 to 2011 and comprised 6,235 women with unilateral breast cancer from 6,230 high risk families that had tested positive for BRCA1 (n = 1,154) or BRCA2 (n = 575) mutations or tested negative (n = 4,501). Cumulative contralateral breast cancer risks were calculated using the Kaplan-Meier product-limit method and were compared between groups using the log-rank test. Cox regression analysis was applied to assess the impact of the age at first breast cancer and the familial history stratified by mutation status. Results: The cumulative risk of contralateral breast cancer 25 years after first breast cancer was 44.1% (95%CI, 37.6% to 50.6%) for patients from BRCA1 positive families, 33.5% (95%CI, 22.4% to 44.7%) for patients from BRCA2 positive families and 17.2% (95%CI, 14.5% to 19.9%) for patients from families that tested negative for BRCA1/2 mutations. Younger age at first breast cancer was associated with a higher risk of contralateral breast cancer. For women who had their first breast cancer before the age of 40 years, the cumulative risk of contralateral breast cancer after 25 years was 55.1% for BRCA1, 38.4% for BRCA2, and 28.4% for patients from BRCA1/2 negative families. If the first breast cancer was diagnosed at the age of 50 or later, 25-year cumulative risks were 21.6% for BRCA1, 15.5% for BRCA2, and 12.9% for BRCA1/2 negative families. Conclusions: Contralateral breast cancer risk in patients from high risk families that tested negative for BRCA1/2 mutations is similar to the risk in patients with sporadic breast cancer. Thus, the mutation status should guide decision making for contralateral mastectomy.


Related Articles

  • Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients. Dodova, Rumyana Ivanova; Mitkova, Atanaska Velichkova; Dacheva, Daniela Rosenova; Hadjo, Lina Basam; Vlahova, Alexandrina Ivanova; Taushanova-Hadjieva, Margarita Stoyanova; Valev, Spartak Stoyanov; Caulevska, Marija Mitko; Popova, Stanislava Dimitrova; Popov, Ivan Emilov; Dikov, Tihomir Iliichev; Sedloev, Theophil Angelov; Ionkov, Atanas Stefanov; Timcheva, Konstanta Velinova; Christova, Svetlana Liubomirova; Kremensky, Ivo Marinov; Mitev, Vanio Ivanov; Kaneva, Radka Petrova // BMC Cancer;Jul2015, Vol. 15 Issue 1, p1 

    Background: About 3885 women are diagnosed with breast cancer and 1285 die from the disease each year in Bulgaria. However no genetic testing to identify the mutations in high-risk families has been provided so far. Methods: We evaluated 200 Bulgarian women with primary invasive breast cancer...

  • Analysis of BRCA1and BRCA2 large genomic rearrangements in Sri Lankan familial breast cancer patients and at risk individuals. Silva, Sumadee De; Tennekoon, Kamani Hemamala; Karunanayake, Eric Hamilton; Amarasinghe, Indrani; Angunawela, Preethika // BMC Research Notes;2014, Vol. 7 Issue 1, p2 

    Background Majority of mutations found to date in the BRCA1/BRCA2 genes in breast and/or ovarian cancer families are point mutations or small insertions and deletions scattered over the coding sequence and splice junctions. Such mutations and sequence variants of BRCA1 and BRCA2 genes were...

  • Women do not automatically have a higher risk of getting breast cancer just because someone else in the family has tested positive for breast cancer genes, US researchers said.  // MondayMorning;11/7/2011, Vol. 19 Issue 40, p1 

    The article presents information that women do not have the risk of getting breast cancer if their family members have tested positive for breast cancer genes. It states that 12-13 percent of women in the U.S have the chances of developing breast cancer in their life time and only five to 10...

  • Genetic risk transmission in a family affected by familial breast cancer. Pilato, Brunella; De Summa, Simona; Danza, Katia; Lacalamita, Rosanna; Lambo, Rossana; Sambiasi, Domenico; Paradiso, Angelo; Tommasi, Stefania // Journal of Human Genetics;Jan2014, Vol. 59 Issue 1, p51 

    Breast Cancer is the most common malignancy among women. Family history is the strongest single predictor of breast cancer risk, and thus great attention has been focused on BRCA1 and BRCA2 genes whose mutations lead to a high risk of developing this disease. Today, only 25% of high- and...

  • Genetics: Relative risk. Velasquez-Manoff, Moises // Nature;11/19/2015 Supplement, Vol. 527 Issue s7578, pS116 

    The article discusses risk factors associated with breast cancer, focusing specifically on mutations in the BRCA genes. It covers research that suggests additional factors such as exposure to oestrogen can influence the risk of the disease in women who may be predisposed based on family medical...

  • Clinical Application of Micronucleus Test: A Case-Control Study on the Prediction of Breast Cancer Risk/Susceptibility. Bolognesi, Claudia; Bruzzi, Paolo; Gismondi, Viviana; Volpi, Samantha; Viassolo, Valeria; Pedemonte, Simona; Varesco, Liliana // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    The micronucleus test is a well-established DNA damage assay in human monitoring. The test was proposed as a promising marker of cancer risk/susceptibility mainly on the basis of studies on breast cancer. Our recent meta-analysis showed that the association between micronuclei frequency, either...

  • Trends in the distribution of breast cancer over time in the southeast of Scotland and review of the literature. Aljarrah, A.; Miller, W. R. // Ecancermedicalscience;2014, Vol. 8 Issue 413-446, p1 

    Introduction: Breast cancer is the most common form of malignancy in Scottish women, and its incidence appears to be increasing with time. It is therefore important to identify factors associated with risk and outcome. Whilst breast cancer occurs equally in the right and left breasts, tumours...

  • Micronutrients Involved in One-Carbon Metabolism and Risk of Breast Cancer Subtypes. Cancarini, Ilaria; Krogh, Vittorio; Agnoli, Claudia; Grioni, Sara; Matullo, Giuseppe; Pala, Valeria; Pedraglio, Samuele; Contiero, Paolo; Riva, Cristina; Muti, Paola; Sieri, Sabina // PLoS ONE;9/16/2015, Vol. 10 Issue 9, p1 

    Background: Vitamins involved in one-carbon metabolism are hypothesized to influence breast cancer (BC) risk. However, epidemiologic studies that examined associations between B vitamin intake and BC risk have provided inconsistent results. We prospectively examined, in the Italian ORDET...

  • Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies. Evans, D. Gareth; Harkness, Elaine; Lalloo, Fiona; Howell, Anthony // Journal of Medical Genetics;Sep2014, Vol. 51 Issue 9, p573 

    Background The risks of breast cancer associated with BRCA1 and BRCA2 mutations vary considerably across studies but few have assessed prospective risks, which are likely to provide more reliable risk estimates for women undergoing presymptomatic testing. Methods Prospective breast cancer risks...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics